This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waxman, D. J. Articles by Schwartz, P. S. Search for Related Content PubMed PubMed Citation Articles by Waxman, D. J. Articles by Schwartz, P. S. Related Collections Therapeutics and Targets Therapeutics and Targets: Drug Mechanisms and Resistance

Harnessing Apoptosis for Improved Anticancer Gene Therapy

Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, Massachusetts

ABSTRACT

Advances in our understanding of the mechanisms by which tumor cells detect drug-induced DNA damage leading to apoptotic death have aided in the design of novel, potentially more selective strategies for cancer treatment. Several of these strategies use proapoptotic factors and have shown promise in sensitizing tumor cells to the cytotoxic actions of traditional cancer chemotherapeutic drugs. Although antiapoptotic factors are generally regarded as poor prognostic factors for successful cancer chemotherapy, strategies that use antiapoptotic factors in combination with suicide or other gene therapies can also be considered. The introduction of antiapoptotic factors that act downstream of drug-induced mitochondrial transition delays, but does not block, the ultimate cytotoxic response to cancer chemotherapeutic drugs that activate a mitochondrial pathway of cell death. Recent studies using the cytochrome P-450 prodrug cyclophosphamide exemplify how the antiapoptotic, caspase-inhibitory baculovirus protein p35 can be combined with P-450 gene-directed enzyme prodrug therapy to prolong localized, intratumoral production of cytotoxic drug metabolites without inducing tumor cell drug resistance. This model may be adapted to other gene therapies, including those that target death receptor pathways, to maximize the production of soluble, bystander cytotoxic factors and prodrug metabolites and thereby amplify the therapeutic response.

This article has been cited by other articles:

				L. Shkreta, U. Froehlich, E. R. Paquet, J. Toutant, S. A. Elela, and B. Chabot Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes Mol. Cancer Ther., June 1, 2008; 7(6): 1398 - 1409. [Abstract] [Full Text] [PDF]

				O. Fromigue, Z. Hamidouche, and P. J. Marie Statin-Induced Inhibition of 3-Hydroxy-3-Methyl Glutaryl Coenzyme A Reductase Sensitizes Human Osteosarcoma Cells to Anticancer Drugs J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 595 - 600. [Abstract] [Full Text] [PDF]

				J. Ma and D. J. Waxman Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment Mol. Cancer Ther., November 1, 2007; 6(11): 2879 - 2890. [Abstract] [Full Text] [PDF]

				C. Carlo-Stella, C. Lavazza, A. Locatelli, L. Vigano, A. M. Gianni, and L. Gianni Targeting TRAIL Agonistic Receptors for Cancer Therapy Clin. Cancer Res., April 15, 2007; 13(8): 2313 - 2317. [Abstract] [Full Text] [PDF]

				Y. Jounaidi, C.-S. Chen, G. J. Veal, and D. J. Waxman Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol. Cancer Ther., March 1, 2006; 5(3): 541 - 555. [Abstract] [Full Text] [PDF]

				A. C. Ranganathan, L. Zhang, A. P. Adam, and J. A. Aguirre-Ghiso Functional Coupling of p38-Induced Up-regulation of BiP and Activation of RNA-Dependent Protein Kinase-Like Endoplasmic Reticulum Kinase to Drug Resistance of Dormant Carcinoma Cells Cancer Res., February 1, 2006; 66(3): 1702 - 1711. [Abstract] [Full Text] [PDF]

				D. Ravi, H. Muniyappa, and K. C. Das Endogenous Thioredoxin Is Required for Redox Cycling of Anthracyclines and p53-dependent Apoptosis in Cancer Cells J. Biol. Chem., December 2, 2005; 280(48): 40084 - 40096. [Abstract] [Full Text] [PDF]

				D. S. Riddick, C. Lee, S. Ramji, E. C. Chinje, R. L. Cowen, K. J. Williams, A. V. Patterson, I. J. Stratford, C. S. Morrow, A. J. Townsend, et al. CANCER CHEMOTHERAPY AND DRUG METABOLISM Drug Metab. Dispos., August 1, 2005; 33(8): 1083 - 1096. [Abstract] [Full Text] [PDF]

				K. Nakayama, R. G. Pergolizzi, and R. G. Crystal Gene Transfer-Mediated Pre-mRNA Segmental Trans-splicing As a Strategy to Deliver Intracellular Toxins for Cancer Therapy Cancer Res., January 1, 2005; 65(1): 254 - 263. [Abstract] [Full Text] [PDF]